Endothelin and endothelin receptor antagonism in portopulmonary hypertension (Q36570852)

15 August 2017

1 reference

title

Endothelin and endothelin receptor antagonism in portopulmonary hypertension (English)

1 reference

15 August 2017

3

A L Gerbes

1 reference

15 August 2017

W Neuhofer

1

1 reference

15 August 2017

V Gülberg

series ordinal

2

1 reference

15 August 2017

publication date

1 September 2006

1 reference

European Journal of Clinical Investigation

15 August 2017

published in

1 reference

15 August 2017

volume

36 Suppl 3

1 reference

15 August 2017

page(s)

54-61

1 reference

Pulmonary-Hepatic vascular Disorders (PHD).

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Pulmonary hypertension in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Portopulmonary hypertension in decompensated cirrhosis with refractory ascites

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Portopulmonary hypertension: a tale of two circulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

The endothelin system in pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Cellular and molecular pathobiology of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

A novel potent vasoconstrictor peptide produced by vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Endothelin system: the double-edged sword in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Cell survival in the hostile environment of the renal medulla

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Vascular responses to endothelin-1 following inhibition of nitric oxide synthesis in the conscious rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Fibroblast matrix gene expression and connective tissue remodeling: role of endothelin-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Growth regulatory properties of endothelins

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Endothelin 1 does not play a major role in the homeostasis of arterial pressure in cirrhotic rats with ascites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

GENERAL AND REGIONAL CIRCULATORY ALTERATIONS IN CIRRHOSIS OF THE LIVER.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Endothelin 1 is overexpressed in human cirrhotic liver and exerts multiple effects on activated hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Seminars in medicine of the Beth Israel Hospital, Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Endothelin receptors in rat liver: lipocytes as a contractile target for endothelin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Endothelin receptor antagonists in pulmonary arterial hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Expression of endothelin-1 in the lungs of patients with pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Elevated levels of plasma endothelin-1 in young patients with pulmonary hypertension caused by congenital heart disease are decreased after successful surgical repair

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Endothelin-1- and endothelin-receptors in lung biopsies of patients with pulmonary hypertension due to congenital heart disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Endothelin mediates pulmonary vascular remodelling in a canine model of chronic embolic pulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Safety and tolerability of bosentan in adults with Eisenmenger physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Progressive splenomegaly after epoprostenol therapy in portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Bosentan therapy for portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Endothelin-receptor antagonist treatment of portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Use of oral endothelin-receptor antagonist bosentan in the treatment of portopulmonary hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Successful treatment of severe portopulmonary hypertension after liver transplantation by bosentan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Successful switch from inhalative iloprost to oral bosentan in portopulmonary hypertension associated with liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Endothelin and vascular function in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

Endothelin is an important determinant of renal function in a rat model of acute liver and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111/J.1365-2362.2006.01690.X

10.1111/J.1365-2362.2006.01690.X

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference